CELC
Price
$10.24
Change
+$0.25 (+2.50%)
Updated
Apr 17 closing price
Capitalization
387.48M
30 days until earnings call
PHVS
Price
$14.00
Change
+$0.28 (+2.04%)
Updated
Apr 17 closing price
Capitalization
762.9M
18 days until earnings call
Ad is loading...

CELC vs PHVS

Header iconCELC vs PHVS Comparison
Open Charts CELC vs PHVSBanner chart's image
Celcuity
Price$10.24
Change+$0.25 (+2.50%)
Volume$165.33K
Capitalization387.48M
Pharvaris
Price$14.00
Change+$0.28 (+2.04%)
Volume$10.09K
Capitalization762.9M
CELC vs PHVS Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. PHVS commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and PHVS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (CELC: $10.24 vs. PHVS: $14.00)
Brand notoriety: CELC and PHVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 57% vs. PHVS: 26%
Market capitalization -- CELC: $387.48M vs. PHVS: $762.9M
CELC [@Biotechnology] is valued at $387.48M. PHVS’s [@Biotechnology] market capitalization is $762.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whilePHVS’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • PHVS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CELC and PHVS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while PHVS’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 2 bearish.
  • PHVS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CELC is a better buy in the short-term than PHVS.

Price Growth

CELC (@Biotechnology) experienced а +18.38% price change this week, while PHVS (@Biotechnology) price change was +17.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

CELC is expected to report earnings on Aug 07, 2025.

PHVS is expected to report earnings on Jul 25, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHVS($763M) has a higher market cap than CELC($387M). CELC YTD gains are higher at: -21.772 vs. PHVS (-26.969). CELC has higher annual earnings (EBITDA): -85.45M vs. PHVS (-127.53M). PHVS has more cash in the bank: 305M vs. CELC (264M). PHVS has less debt than CELC: PHVS (117K) vs CELC (97.2M). CELC (0) and PHVS (0) have equivalent revenues.
CELCPHVSCELC / PHVS
Capitalization387M763M51%
EBITDA-85.45M-127.53M67%
Gain YTD-21.772-26.96981%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M305M87%
Total Debt97.2M117K83,077%
FUNDAMENTALS RATINGS
CELC: Fundamental Ratings
CELC
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
83
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
78
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CELCPHVS
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CDOZX36.100.38
+1.06%
Columbia Dividend Opportunity Inst
BBTGX28.970.23
+0.80%
Sterling Capital Behav Lg Cp Val Eq A
PPIMX6.840.04
+0.59%
Principal MidCap Growth III Inst
JMGPX41.890.18
+0.43%
JPMorgan Mid Cap Growth R3
RMQHX387.57-0.15
-0.04%
Rydex Monthly Rbl NASDAQ-100® 2x Strt H

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+2.50%
ABOS - CELC
46%
Loosely correlated
-8.08%
PRME - CELC
45%
Loosely correlated
N/A
CLDX - CELC
44%
Loosely correlated
+2.81%
ELVN - CELC
42%
Loosely correlated
+2.86%
NUVB - CELC
42%
Loosely correlated
+4.79%
More

PHVS and

Correlation & Price change

A.I.dvisor tells us that PHVS and MLTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHVS and MLTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHVS
1D Price
Change %
PHVS100%
+2.04%
MLTX - PHVS
30%
Poorly correlated
+3.67%
ATXS - PHVS
29%
Poorly correlated
+1.51%
MGTX - PHVS
27%
Poorly correlated
+1.69%
CELC - PHVS
27%
Poorly correlated
+2.50%
RVMD - PHVS
27%
Poorly correlated
+1.55%
More